NeuroPace Inc
NPCE
Get informed when a big investor buys or sells
+ FollowMarket Cap$532.89M
Close$
Share Statistics
| Market cap | $532.89 Million |
|---|---|
| Enterprise Value | $588.69 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.66 |
| Beta | 1.88 |
| Outstanding Shares | 33,716,813 |
Return
| Return on Equity | -89.35% |
|---|---|
| Return on Assets | -13.06% |
| Return on Invested Capital | -20.26% |
Valuation & Multiples
| P/E Ratio | -24.44 |
|---|---|
| PEG | - |
| Price to Sales | 7.96 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 5.91 |
| Enterprise Value to EBIT | -35.13 |
| Enterprise Value to Net Income | -46 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 4.88 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$21.65 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$-0.19
Average shareholder expectationRevenue Estimate
$22.56 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 11,200▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.85%▲ 1.48% |
|---|---|
| Total Invested | $347.86M▼ 14.30% |
| Investors Holding | 113▲ 13.00% |
ESG Score
No data
About NeuroPace Inc
152 employeesBased in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and ...